Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease

Immunological Reviews

Volumn 244, Issue 1, 2011, Pages 115-133

  Rickert, Robert C ^a   Jellusova, Julia ^a   Miletic, Ana V ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

B cell; BAFF; BCMA; CD40; NF B; TACI

Indexed keywords

APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; B CELL MATURATION ANTIGEN; B LYMPHOCYTE DIFFERENTIATION FACTOR; BAG 1 PROTEIN; BCR ABL PROTEIN; BELIMUMAB; CD23 ANTIGEN; CD27 ANTIGEN; CD40 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT COMPONENT C3D RECEPTOR; I KAPPA B KINASE BETA; IMMUNOGLOBULIN D; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M; INHIBITOR OF APOPTOSIS PROTEIN 1; INTERLEUKIN 6; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P50; PROTEIN P52; SYNDECAN 1; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CANONICAL ANALYSIS; CD4+ T LYMPHOCYTE; CYTOLOGY; FOLLICULAR DENDRITIC CELL; HUMAN; MULTIPLE SCLEROSIS; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TONSIL;

ANIMALS; ANTIGENS, CD40; AUTOIMMUNE DISEASES; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; B-CELL MATURATION ANTIGEN; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION; HUMANS; IMMUNITY, INNATE; MICE; MICE, TRANSGENIC; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 80054875478     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2011.01067.x     Document Type: Review

References (231)

1. Allman DM, Ferguson SE, Cancro MP. Peripheral B cell maturation. I. Immature peripheral B cells in adults are heat-stable antigenhi and exhibit unique signaling characteristics. J Immunol 1992;149:2533-2540.
2. Carsetti R, Kohler G, Lamers M. Transitional B cells are the target of negative selection in the B cell compartment. J Exp Med 1995;181:2129-2140.
3. Loder F, et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med 1999;190:75-89.
4. Allman D, Lindsley RC, DeMuth W, Rudd K, Shinton SA, Hardy RR. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 2001;167:6834-6840.
5. Schiemann B, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001;293:2111-2114.
6. Chung JB, Sater RA, Fields ML, Erikson J, Monroe JG. CD23 defines two distinct subsets of immature B cells which differ in their responses to T cell help signals. Int Immunol 2002;14:157-166.
7. Allen CD, Cyster JG. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin Immunol 2008;20:14-25.
8. Pillai S, Cariappa A. The follicular versus marginal zone B lymphocyte cell fate decision. Nat Rev Immunol 2009;9:767-777.
9. Sun S-C, Ley SC. New insights into NF-[kappa]B regulation and function. Trends Immunol 2008;29:469-478.
10. Viatour P, Merville M-P, Bours V, Chariot A. Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005;30:43-52.
11. Kamata H, Tsuchiya Y, Asano T. IκBβ is a positive and negative regulator of NF-κB activity during inflammation. Cell Res 2010;20:1178-1180.
12. Cheng JD, Ryseck RP, Attar RM, Dambach D, Bravo R. Functional redundancy of the nuclear factor kappa B inhibitors I kappa B alpha and I kappa B beta. J Exp Med 1998;188:1055-1062.
13. Scheibel M, et al. IkappaBbeta is an essential co-activator for LPS-induced IL-1beta transcription in vivo. J Exp Med 2010;207:2621-2630.
14. Rao P, et al. IkappaBbeta acts to inhibit and activate gene expression during the inflammatory response. Nature 2010;466:1115-1119.
15. Shih VF-S, Tsui R, Caldwell A, Hoffmann A. A single NF[kappa]B system for both canonical and non-canonical signaling. Cell Res 2011;21:86-102.
16. Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 2002;298:1241-1245.
17. Perkins ND. Integrating cell-signalling pathways with NF-[kappa]B and IKK function. Nat Rev Mol Cell Biol 2007;8:49-62.
18. Li ZW, Omori SA, Labuda T, Karin M, Rickert RC. IKK beta is required for peripheral B cell survival and proliferation. J Immunol 2003;170:4630-4637.
19. Bonizzi G, et al. Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J 2004;23:4202-4210.
20. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 1999;284:321-325.
21. Alcamo E, et al. Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for NF-kappa B in leukocyte recruitment. J Immunol 2001;167:1592-1600.
22. Doi TS, et al. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci USA 1999;96:2994-2999.
23. Gerondakis S, et al. Unravelling the complexities of the NF-[kappa]B signalling pathway using mouse knockout and transgenic models. Oncogene 2006;25:6781-6799.
24. Sun S-C. Non-canonical NF-[kappa]B signaling pathway. Cell Res 2011;21:71-85.
25. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Science's STKE 2006;2006:re13.
26. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-288.
27. Hayden MS, West AP, Ghosh S. NF-κB and the immune response. Oncogene 2006;25:6758-6780.
28. Siebenlist U, Brown K, Claudio E. Control of lymphocyte development by nuclear factor-[kappa]B. Nat Rev Immunol 2005;5:435-445.
29. Kaisho T, et al. IκB Kinase α is essential for mature B cell development and function. J Exp Med 2001;193:417-426.
30. Pasparakis M, Schmidt-Supprian M, Rajewsky K. I kappa B kinase signaling is essential for maintenance of mature B cells. J Exp Med 2002;196:743-752.
31. Mills DM, Bonizzi G, Karin M, Rickert RC. Regulation of late B cell differentiation by intrinsic IKKalpha-dependent signals. Proc Natl Acad Sci U S A 2007;104:6359-6364.
32. Day ES, et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 2005;44:1919-1931.
33. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000;10:785-788.
34. Gross JA, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-999.
35. Kimberley FC, et al. The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking. FASEB J 2009;23:1584-1595.
36. Bossen C, et al. Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses. Eur J Immunol 2011;41:787-797.
37. Lopez-Fraga M, Fernandez R, Albar JP, Hahne M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep 2001;2:945-951.
38. Liu Y, et al. Ligand-receptor binding revealed by the TNF family member TALL-1. Nature 2003;423:49-56.
39. Bossen C, et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008;111:1004-1012.
40. Schneider P, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-1756.
41. Moore PA, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285:260-263.
42. Chu VT, Enghard P, Riemekasten G, Berek C. In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol 2007;179:5947-5957.
43. Moisini I, Davidson A. BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 2009;158:155-163.
44. Mihalcik SA, Tschumper RC, Jelinek DF. Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies. Cell Cycle 2010;9:4884-4892.
45. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003;198:937-945.
46. Miller DJ, Hayes CE. Phenotypic and genetic characterization of a unique B lymphocyte deficiency in strain A/WySnJ mice. Eur J Immunol 1991;21:1123-1130.
47. Thompson JS, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001;293:2108-2111.
48. Yan M, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 2001;11:1547-1552.
49. Hoag KA, et al. A quantitative-trait locus controlling peripheral B-cell deficiency maps to mouse Chromosome 15. Immunogenetics 2000;51:924-929.
50. Lentz VM, Cancro MP, Nashold FE, Hayes CE. Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/WySnJ mouse. J Immunol 1996;157:598-606.
51. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 2004;173:2245-2252.
52. Meyer-Bahlburg A, Andrews SF, Yu KOA, Porcelli SA, Rawlings DJ. Characterization of a late transitional B cell population highly sensitive to BAFF-mediated homeostatic proliferation. J Exp Med 2008;205:155-168.
53. Stadanlick JE, et al. Tonic B cell antigen receptor signals supply an NF-[kappa]B substrate for prosurvival BLyS signaling. Nat Immunol 2008;9:1379-1387.
54. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002;168:5993-5996.
55. Smith SH, Cancro MP. Cutting edge: B cell receptor signals regulate BLyS receptor levels in mature B Cells and their immediate progenitors. J Immunol 2003;170:5820-5823.
56. Rowland SL, Leahy KF, Halverson R, Torres RM, Pelanda R. BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling. J Immunol 2010;185:4570-4581.
57. Gorelik L, et al. Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol 2004;172:762-766.
58. Rahman ZSM, Manser T. B cells expressing Bcl-2 and a signaling-impaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. J Immunol 2004;173:6179-6188.
59. Tardivel A, et al. The anti-apoptotic factor Bcl-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF. Eur J Immunol 2004;34:509-518.
60. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009;9:491-502.
61. Kalled SL. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 2006;18:290-296.
62. Rahman ZS, Rao SP, Kalled SL, Manser T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003;198:1157-1169.
63. Vora KA, et al. Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol 2003;171:547-551.
64. Ng LG, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004;173:807-817.
65. Benson MJ, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008;180:3655-3659.
66. Scholz JL, et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Nat Acad Sci 2008;105:15517-15522.
67. Do RKG, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000;192:953-964.
68. Brenner D, Mak TW. Mitochondrial cell death effectors. Curr Opin Cell Biol 2009;21:871-877.
69. Takeuchi O, Fisher J, Suh H, Harada H, Malynn BA, Korsmeyer SJ. Essential role of BAX, BAK in B cell homeostasis and prevention of autoimmune disease. Proc Natl Acad Sci USA 2005;102:11272-11277.
70. Bouillet P, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999;286:1735-1738.
71. Labi V, et al. Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates gamma irradiation-induced thymic lymphoma development. J Exp Med 2008;205:641-655.
72. Chen L, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403.
73. Kuwana T, et al. BH3 domains of BH3-only proteins differentially regulate bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005;17:525-535.
74. Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 2005;202:1363-1374.
75. Hatada EN, et al. NF-{kappa}B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-{kappa}B2 p100 to p52 in quiescent mature B cells. J Immunol 2003;171:761-768.
76. Enzler T, et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006;25:403-415.
77. Motoyama N, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995;267:1506-1510.
78. Mikkers H, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004;24:6104-6115.
79. Woodland RT, et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 2008;111:750-760.
80. Giltiay NV, Lu Y, Allman D, Jorgensen TN, Li X. The adaptor molecule Act1 regulates BAFF responsiveness and self-reactive B cell selection during transitional B cell maturation. J Immunol 2010;185:99-109.
81. Vikstrom I, et al. Mcl-1 Is essential for germinal center formation and B cell memory. Science 2010;330:1095-1099.
82. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003;426:671-676.
83. Monroe JG, Dorshkind K. Fate decisions regulating bone marrow and peripheral B lymphocyte development. Adv Immunol 2007;95:1-50.
84. Sandel PC, Monroe JG. Negative selection of immature B cells by receptor editing or deletion is determined by site of antigen encounter. Immunity 1999;10:289-299.
85. Henderson RB, et al. A novel Rac-dependent checkpoint in B cell development controls entry into the splenic white pulp and cell survival. J Exp Med 2010;207:837-853.
86. Chan TD, Gardam S, Gatto D, Turner VM, Silke J, Brink R. In vivo control of B-cell survival and antigen-specific B-cell responses. Immunol Rev 2010;237:90-103.
87. Xie P, Kraus ZJ, Stunz LL, Bishop GA. Roles of TRAF molecules in B lymphocyte function. Cytokine Growth Factor Rev 2008;19:199-207.
88. Hacker H, Tseng PH, Karin M. Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol 2011;11:457-468.
89. Xu L-G, Shu H-B. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-κB activation and IL-10 production. J Immunol 2002;169:6883-6889.
90. Ni C-Z, et al. Key molecular contacts promote recognition of the BAFF receptor by TNF receptor-associated factor 3: implications for intracellular signaling regulation. J Immunol 2004;173:7394-7400.
91. Mackay F, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-1710.
92. Grech AP, Amesbury M, Chan T, Gardam S, Basten A, Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 2004;21:629-642.
93. Gardam S, Sierro F, Basten A, Mackay F, Brink R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008;28:391-401.
94. Xie P, Stunz LL, Larison KD, Yang B, Bishop GA. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 2007;27:253-267.
95. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-[kappa]B2 in maturing B cells. Nat Immunol 2002;3:958-965.
96. Senftleben U, et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001;293:1495-1499.
97. Kayagaki N, et al. BAFF/BLyS receptor 3 binds the b cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-[kappa]B2. Immunity 2002;17:515-524.
98. Liao G, Zhang M, Harhaj EW, Sun S-C. Regulation of the NF-{kappa}B-inducing kinase by tumor necrosis factor Receptor-associated factor 3-induced degradation. J Biol Chem 2004;279:26243-26250.
99. Vallabhapurapu S, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-[kappa]B signaling. Nat Immunol 2008;9:1364-1370.
100. Zarnegar BJ, et al. Noncanonical NF-[kappa]B activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008;9:1371-1378.
101. Sanjo H, Zajonc DM, Braden R, Norris PS, Ware CF. Allosteric regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxin-beta receptor. J Biol Chem 2010;285:17148-17155.
102. Gardam S, et al. Deletion of cIAP1 and cIAP2 in murine B lymphocytes constitutively activates cell survival pathways and inactivates the germinal center response. Blood 2011;117:4041-4051.
103. Conze DB, Zhao Y, Ashwell JD. Non-canonical NF-kappaB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2. PLoS Biol 2010;8:e1000518.
104. Sasaki Y, et al. NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells. Proc Nat Acad Sci 2008;105:10883-10888.
105. Razani B, et al. Negative feedback in noncanonical NF-{kappa}B signaling modulates NIK stability through IKK{alpha}-mediated phosphorylation. Sci Signal 2010;3:ra41.
106. Yamada T, et al. Abnormal immune function of hemopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-kappa B-inducing kinase. J Immunol 2000;165:804-812.
107. Mackay F, Figgett WA, Saulep D, Lepage M, Hibbs ML. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev 2010;237:205-225.
108. Zarnegar B, Yamazaki S, He JQ, Cheng G. Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci U S A 2008;105:3503-3508.
109. O'Mahony A, Lin X, Geleziunas R, Greene WC. Activation of the heterodimeric Ikappa B kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions. Mol Cell Biol 2000;20:1170-1178.
110. Mecklenbrauker I, Kalled SL, Leitges M, Mackay F, Tarakhovsky A. Regulation of B-cell survival by BAFF-dependent PKCdelta-mediated nuclear signalling. Nature 2004;431:456-461.
111. Miyamoto A, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase C[delta]. Nature 2002;416:865-869.
112. Mecklenbrauker I, Saijo K, Zheng NY, Leitges M, Tarakhovsky A. Protein kinase Cdelta controls self-antigen-induced B-cell tolerance. Nature 2002;416:860-865.
113. DeVries-Seimon TA, Ohm AM, Humphries MJ, Reyland ME. Induction of apoptosis is driven by nuclear retention of protein kinase C delta. J Biol Chem 2007;282:22307-22314.
114. Sasaki Y, et al. Canonical NF-[kappa]B activity, dispensable for B cell development, replaces baff-receptor signals and promotes B cell proliferation upon activation. Immunity 2006;24:729-739.
115. Baracho G, Miletic A, Omori S, Cato M, Rickert R. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol 2011;23:178-183.
116. Fruman DA, Cantley LC. Phosphoinositide 3-kinase in immunological systems. Semin Immunol 2002;14:7-18.
117. Leslie NR, Downes CP. PTEN: the down side of PI 3-kinase signalling. Cell Signal 2002;14:285-295.
118. Patke A, Mecklenbrauker I, Erdjument-Bromage H, Tempst P, Tarakhovsky A. BAFF controls B cell metabolic fitness through a PKC{beta}- and Akt-dependent mechanism. J Exp Med 2006;203:2551-2562.
119. Otipoby KL, et al. BAFF activates Akt and Erk through BAFF-R in an IKK1-dependent manner in primary mouse B cells. Proc Nat Acad Sci 2008;105:12435-12438.
120. Henley T, Kovesdi D, Turner M. B-cell responses to B-cell activation factor of the TNF family (BAFF) are impaired in the absence of PI3K delta. Eur J Immunol 2008;38:3543-3548.
121. So T, Choi H, Croft M. OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling. J Immunol 2011;186:3547-3555.
122. Khan WN. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 2009;183:3561-3567.
123. Shinners NP, et al. Bruton's tyrosine kinase mediates NF-kappa B activation and B cell survival by B cell-activating factor receptor of the TNF-R family. J Immunol 2007;179:3872-3880.
124. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006;21:749-760.
125. Brunet A, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-868.
126. Dengler HS, et al. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol 2008;9:1388-1398.
127. Srinivasan L, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009;139:573-586.
128. Shinohara H, Kurosaki T. Comprehending the complex connection between PKCβ, TAK1, and IKK in BCR signaling. Immunol Rev 2009;232:300-318.
129. Castro I, et al. B cell receptor-mediated sustained c-Rel activation facilitates late transitional B cell survival through control of B cell activating factor receptor and NF-kappaB2. J Immunol 2009;182:7729-7737.
130. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006;18:263-275.
131. Datta SR, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241.
132. You H, et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 2006;203:1657-1663.
133. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000;10:1201-1204.
134. Cancro MP. Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol 2009;9:657-661.
135. Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997;90:1073-1083.
136. Huang X, et al. Homeostatic cell-cycle control by BLyS: induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci U S A 2004;101:17789-17794.
137. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000;404:782-787.
138. Miletic AV, et al. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med 2010;207:2407-2420.
139. Lee KY, D'Acquisto F, Hayden MS, Shim JH, Ghosh S. PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation. Science 2005;308:114-118.
140. Park S-G, et al. The kinase PDK1 integrates T cell antigen receptor and CD28 coreceptor signaling to induce NF-[kappa]B and activate T cells. Nat Immunol 2009;10:158-166.
141. Sommer K, et al. Phosphorylation of the CARMA1 linker controls NF-[kappa]B activation. Immunity 2005;23:561-574.
142. Shinohara H, Maeda S, Watarai H, Kurosaki T. IkappaB kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells. J Exp Med 2007;204:3285-3293.
143. Ferch U, et al. MALT1 directs B cell receptor-induced canonical nuclear factor-[kappa]B signaling selectively to the c-Rel subunit. Nat Immunol 2007;8:984-991.
144. Tusche MW, et al. Differential requirement of MALT1 for BAFF-induced outcomes in B cell subsets. J Exp Med 2009;206:2671-2683.
145. Dejardin E, et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002;17:525-535.
146. Basak S, et al. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 2007;128:369-381.
147. Tucker E, et al. A novel mutation in the Nfkb2 gene generates an NF-kappa B2 "super repressor". J Immunol 2007;179:7514-7522.
148. Groom J, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Investig 2002;109:59-68.
149. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-1319.
150. Zhang J, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10.
151. Chu VT, et al. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 2009;60:2083-2093.
152. Mariette X, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-171.
153. Thien M, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785-798.
154. Lesley R, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004;20:441-453.
155. Ota M, et al. Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol 2010;185:4128-4136.
156. Litinskiy MB, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-829.
157. Liu Z, Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol 2011;32:388-394.
158. Navarra SV, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-731.
159. Batten M, et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004;172:812-822.
160. Novak AJ, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004;104:2247-2253.
161. Novak AJ, et al. Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 2009;69:4217-4224.
162. Pham LV, et al. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-kappaB-inducing kinase while activating both canonical and alternative nuclear factor-kappaB pathways. Blood 2011;117:200-210.
163. Ryan MC, Grewal IS. Targeting of BAFF and APRIL for autoimmunity and oncology. Adv Exp Med Biol 2009;647:52-63.
164. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004;172:3268-3279.
165. Kern C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004;103:679-688.
166. Hildebrand JM, et al. A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. J Exp Med 2010;207:2569-2579.
167. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2010;2:a000109.
168. Schneider P, et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med 2001;194:1691-1698.
169. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007;179:7276-7286.
170. Gras M-P, et al. BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int Immunol 1995;7:1093-1106.
171. Xu S, Lam K-P. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001;21:4067-4074.
172. O'Connor BP, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199:91-98.
173. Chu VT, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 2011;12:151-159.
174. Belnoue E, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008;111:2755-2764.
175. Ingold K, et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005;201:1375-1383.
176. Reijmers RM, et al. Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival. Blood 2011;117:6162-6171.
177. Shu H-B, Johnson H. B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. Proc Nat Acad Sci 2000;97:9156-9161.
178. Hatzoglou A, et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-κB, Elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol 2000;165:1322-1330.
179. Annunziata CM, et al. Frequent engagement of the classical and alternative NF-[kappa]B pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-130.
180. Keats JJ, et al. Promiscuous mutations activate the noncanonical NF-[kappa]B pathway in multiple myeloma. Cancer Cell 2007;12:131-144.
181. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 2010;115:3541-3552.
182. Novak AJ, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004;103:689-694.
183. Mackay F, Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 2008;19:263-276.
184. Groom JR, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007;204:1959-1971.
185. von Bulow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997;278:138-141.
186. Xia X-Z, et al. Taci is a traf-interacting receptor for Tall-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med 2000;192:137-144.
187. He B, et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 2010;11:836-845.
188. Lobito AA, Gabriel TL, Medema JP, Kimberley FC. Disease causing mutations in the TNF and TNFR superfamilies: focus on molecular mechanisms driving disease. Trends Mol Med 2011;17:494-505.
189. Castigli E, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005;37:829-834.
190. Salzer U, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005;37:820-828.
191. Dong X, Hoeltzle MV, Hagan JB, Park MA, Li JT, Abraham RS. Phenotypic and clinical heterogeneity associated with monoallelic TNFRSF13B-A181E mutations in common variable immunodeficiency. Hum Immunol 2010;71:505-511.
192. Garibyan L, Lobito AA, Siegel RM, Call ME, Wucherpfennig KW, Geha RS. Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID). J Clin Investig 2007;117:1550-1557.
193. Lee JJ, et al. The C104R mutant impairs the function of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) through haploinsufficiency. J Allergy Clin Immunol 2010;126: 1234.e2-1241.e2.
194. Lee JJ, et al. The murine equivalent of the A181E TACI mutation associated with common variable immunodeficiency severely impairs B-cell function. Blood 2009;114:2254-2262.
195. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003;18:279-288.
196. von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity 2001;14:573-582.
197. Yan M, et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2001;2:638-643.
198. Castigli E, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005;201:35-39.
199. Mantchev GT, Cortesao CS, Rebrovich M, Cascalho M, Bram RJ. TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens. J Immunol 2007;179:2282-2288.
200. Huard B, et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Investig 2008;118:2887-2895.
201. He B, et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007;26:812-826.
202. Castigli E, et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004;101:3903-3908.
203. Varfolomeev E, et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004;24:997-1006.
204. Moreaux J, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005;106:1021-1030.
205. Quinn J, et al. APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. Blood 2011;117:890-901.
206. da Silva S, et al. Lymphoid proliferations of indeterminate malignant potential arising in adults with common variable immunodeficiency disorders: unusual case studies and immunohistological review in the light of possible causative events. J Clin Immunol 2011;in press.
207. Aruffo A, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993;72:291-300.
208. Allen RC, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993;259:990-993.
209. Korthauer U, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993;361:539-541.
210. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature 1993;361:541-543.
211. Elgueta R, Benson MJ, De Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009;229:152-172.
212. Kawabe T, et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994;1:167-178.
213. Castigli E, et al. CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci USA 1994;91:12135-12139.
214. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK. Visualization of specific B and T lymphocyte interactions in the lymph node. Science 1998;281:96-99.
215. Van den Eertwegh AJ, et al. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J Exp Med 1993;178:1555-1565.
216. Erickson LD, et al. Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J Clin Invest 2002; 109:613-620.
217. Coffey F, Alabyev B, Manser T. Initial clonal expansion of germinal center B cells takes place at the perimeter of follicles. Immunity 2009;30:599-609.
218. Hannedouche S, et al. Oxysterols direct immune cell migration via EBI2. Nature 2011;475:524-527.
219. Liu C, et al. Oxysterols direct B-cell migration through EBI2. Nature 2011;475:519-523.
220. Gatto D, Paus D, Basten A, Mackay CR, Brink R. Guidance of B cells by the orphan G protein-coupled receptor EBI2 shapes humoral immune responses. Immunity 2009;31:259-269.
221. Pereira JP, Kelly LM, Xu Y, Cyster JG. EBI2 mediates B cell segregation between the outer and centre follicle. Nature 2009;460:1122-1126.
222. Han S, Hathcock K, Zheng B, Kepler TB, Hodes R, Kelsoe G. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J Immunol 1995;155:556-567.
223. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011;29:621-663.
224. Matsuzawa A, et al. Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science 2008;321:663-668.
225. Coope HJ, et al. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 2002;21:5375-5385.
226. Gallagher E, et al. Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat Immunol 2007;8:57-63.
227. Kobayashi T, et al. TRAF6 is required for generation of the B-1a B cell compartment as well as T cell-dependent and -independent humoral immune responses. PLoS ONE 2009;4:e4736.
228. Weih DS, Yilmaz ZB, Weih F. Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines. J Immunol 2001;167:1909-1919.
229. Franzoso G, et al. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 1998;187:147-159.
230. Clark EA, Ledbetter JA. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Nat Acad Sci 1986;83:4494-4498.
231. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46:705-716.